PubRank
Search
About
Phase I Biomarker Study (BMS-936558)
Clinical Trial ID NCT01358721
PubWeight™ 67.22
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01358721
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med
2012
52.99
2
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Clin Cancer Res
2013
3.48
3
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.
Nat Rev Clin Oncol
2013
2.64
4
The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry.
Cancer Prev Res (Phila)
2015
2.17
5
Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Semin Oncol
2015
1.45
6
Cancer immunotherapy in clinical practice -- the past, present, and future.
Chin J Cancer
2014
0.98
7
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
Cancer J
2014
0.88
8
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Clin Cancer Res
2016
0.86
9
PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
Cancer Immunol Res
2014
0.85
10
Evolving Concepts: Immunity in Oncology from Targets to Treatments.
J Oncol
2015
0.81
11
Influence of tumors on protective anti-tumor immunity and the effects of irradiation.
Front Oncol
2013
0.79
12
Cellular and molecular immunology of lung cancer: therapeutic implications.
Expert Rev Clin Immunol
2014
0.79
13
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
J Transl Med
2016
0.77
14
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.
ESMO Open
2016
0.77
15
New clinical advances in immunotherapy for the treatment of solid tumours.
Immunology
2015
0.76
16
An update on current management of advanced renal cell cancer, biomarkers, and future directions.
Ann Cancer Res
2015
0.76
17
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.
BioDrugs
2014
0.76
Next 100